Nanoparticle-and liposome-carried drugs: New strategies for active targeting and drug delivery across blood-brain barrier

The blood-brain barrier (BBB), the unusual microvascular endothelial interface between the central nervous system (CNS) and the circulatory system, is a major hindrance to drug delivery in the brain parenchyma. Besides the absence of fenestrations and the abundance of tight junctions, ATP-binding ca...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2013
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/23802
Acceso en línea:
https://doi.org/10.2174/1389200211314060001
https://repository.urosario.edu.co/handle/10336/23802
Palabra clave:
Dactinomycin
Dasatinib
Daunorubicin
Docetaxel
Doxorubicin
Epirubicin
Erlotinib
Etoposide
Gefitinib
Indinavir
Irinotecan
Ketoconazole
Lamivudine
Lapatinib
Liposome
Methotrexate
Mitoxantrone
Nanoparticle
Nelfinavir
Paclitaxel
Probenecid
Saquinavir
Sorafenib
Teniposide
Topotecan
Unindexed drug
Verlukast
Vinblastine
Vincristine
Zidovudine
Blood brain barrier
Controlled drug release
Degenerative disease
Drug coating
Drug degradation
Drug delivery system
Drug distribution
Drug mechanism
Drug penetration
Drug synthesis
Drug targeting
Epilepsy
Gene therapy
Glioblastoma
Human
Human immunodeficiency virus infection
Hydrophilicity
Hydrophobicity
In vivo study
Lipophilicity
Nanoencapsulation
Nonhuman
Parenchyma
Physical chemistry
Review
Surface property
Animals
Atp-binding cassette transporters
Biological transport
Blood-brain barrier
Humans
Liposomes
Nanoparticles
Pharmaceutical preparations
Atp-binding cassette transporters
Blood-brain barrier
Central nervous system
Drug delivery
Liposomes
Nanoparticles
Rights
License
Abierto (Texto Completo)
Description
Summary:The blood-brain barrier (BBB), the unusual microvascular endothelial interface between the central nervous system (CNS) and the circulatory system, is a major hindrance to drug delivery in the brain parenchyma. Besides the absence of fenestrations and the abundance of tight junctions, ATP-binding cassette (ABC) transporters critically reduce drug entry within the CNS, as they carry many drugs back into the bloodstream. Nanoparticle-and liposome-carried drugs, because of their increased cellular uptake and reduced efflux through ABC transporters, have been developed in recent times to circumvent the low drug permeability of the BBB. This review discusses the role of ABC transporters in controlling drug penetration into the brain parenchyma, the rationale for using nanoparticle-and liposome-based strategies to increase drug delivery across the BBB and new therapeutic strategies for using nanoparticle-and liposome-carried drugs in different conditions, ranging from CNS tumors and neurodegenerative diseases to viral infections and epilepsy. © 2013 Bentham Science Publishers.